Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acacia Pharma Ltd
• Treatments: Aprepitant; Dexamethasone; Fosaprepitant; Ondansetron

Criteria

Inclusion criteria

• Male or female patients ≥ 18 years of age

• Ability and willingness to give written informed consent

• Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first cisplatin chemotherapy infusion at a dose of ≥70 mg/m2 (males and females); or (ii) a first infusion of cyclophosphamide at a dose of 500-1500 mg/m2 in combination with either epirubicin at a dose of 60-100 mg/m2 or doxorubicin at a dose of 40-60 mg/m2 (females only)

• Karnofsky performance score ≥ 60%

• Adequate cardiac, hepatic and renal function

• QTc interval < 500 ms

• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN)

• Bilirubin < 5 x ULN

• Creatinine < 3 x ULN

• Adequate haematological function

• Haemoglobin ≥ 8 g/dL

• White blood count ≥ 3.0 x 109/L

• Platelet count ≥ 100 x 109/L

• For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards

Exclusion Criteria

• Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC, any other chemotherapeutic agent with a high or moderate emetic risk

• Patients who have previously received anti-neoplastic chemotherapy

• Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their chemotherapy

• Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin or AC administration

• Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or confirmed prolactin-dependent breast cancer) or phaeochromocytoma

• Patients with a pre-existing vestibular disorder

• Patients being treated with regular anti-emetic therapy including corticosteroids

• Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry